throbber

`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`OZEMPIC® safely and effectively. See full prescribing information
`for OZEMPIC.
`
`OZEMPIC (semaglutide) injection, for subcutaneous use
`Initial U.S. Approval: 2017
`
`
`
`
`WARNING: RISK OF THYROID C-CELL TUMORS
`See full prescribing information for complete boxed warning.
`
`In rodents, semaglutide causes thyroid C-cell tumors. It is
`unknown whether OZEMPIC causes thyroid C-cell tumors,
`including medullary thyroid carcinoma (MTC), in humans as
`the human relevance of semaglutide-induced rodent thyroid C-
`cell tumors has not been determined (5.1, 13.1).
` OZEMPIC is contraindicated in patients with a personal or
`family history of MTC or in patients with Multiple Endocrine
`Neoplasia syndrome type 2 (MEN 2). Counsel patients
`regarding the potential risk of MTC and symptoms of thyroid
`tumors (4, 5.1).
`
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙INDICATIONS AND USAGE∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist
`indicated as an adjunct to diet and exercise to improve glycemic control
`in adults with type 2 diabetes mellitus (1).
`
`Limitations of Use:
`Not recommended as first-line therapy for patients inadequately
`
`controlled on diet and exercise (1, 5.1).
`Has not been studied in patients with a history of pancreatitis.
`Consider another antidiabetic therapy (1, 5.2).
`Not indicated for use in type 1 diabetes mellitus or treatment of
`diabetic ketoacidosis (1).
`
`
`
`
`
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE AND ADMINISTRATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`Start at 0.25 mg once weekly. After 4 weeks, increase the dose to
`
`0.5 mg once weekly. If after at least 4 weeks additional glycemic
`control is needed, increase to 1 mg once weekly (2.1).
`Administer once weekly at any time of day, with or without meals
`(2.1).
`If a dose is missed administer within 5 days of missed dose (2.1).
`Inject subcutaneously in the abdomen, thigh, or upper arm (2.2).
`
`
`
`
`
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE FORMS AND STRENGTHS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`Injection: 2 mg/1.5 mL (1.34 mg/mL) available in:
`Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection
`
`(3).
`Single-patient-use pen that delivers 1 mg per injection (3).
`
`
`
`
`
`
`
`
`
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`Personal or family history of medullary thyroid carcinoma or in patients
`
`with Multiple Endocrine Neoplasia syndrome type 2 (4).
`Known hypersensitivity to OZEMPIC or any of the product components
`(4).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`Pancreatitis: Has been reported in clinical trials. Discontinue promptly if
`
`pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2).
`Diabetic Retinopathy Complications: Has been reported in a clinical trial.
`Patients with a history of diabetic retinopathy should be monitored (5.3).
`Never share an OZEMPIC pen between patients, even if the needle is
`changed (5.4).
`Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or
`insulin, consider lowering the dose of the secretagogue or insulin to reduce
`the risk of hypoglycemia (5.5).
`Acute Kidney Injury: Monitor renal function in patients with renal
`impairment reporting severe adverse gastrointestinal reactions (5.6).
`Hypersensitivity Reactions: Discontinue OZEMPIC if suspected and
`promptly seek medical advice (5.7).
` Macrovascular outcomes: There have been no clinical studies establishing
`conclusive evidence of macrovascular risk reduction with semaglutide
`(5.8).
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ADVERSE REACTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`The most common adverse reactions, reported in ≥5% of patients treated with
`OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation
`(6.1).
`
`To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk
`Inc., at 1-888-693-6742 or FDA at 1-800-FDA-1088 or
`www.fda.gov/medwatch.
`
`------------------------------DRUG INTERACTIONS-----------------------------------
`Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of
`concomitantly administered oral medications (7.2).
`
`∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙USE IN SPECIFIC POPULATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
`Females and Males of Reproductive Potential: Discontinue OZEMPIC in women
`at least 2 months before a planned pregnancy due to the long washout period for
`semaglutide (8.3).
`
`See 17 for PATIENT COUNSELING INFORMATION and
`Medication Guide.
` Revised: 12/2017
`
`
`1
`Reference ID: 4190425
`
`

`

`
`
`
`
`
`
`
`8
`
`13
`14
`
`
`USE IN SPECIFIC POPULATIONS
`8.1 Pregnancy
`8.2 Lactation
`8.3 Females and Males of Reproductive Potential
`8.4 Pediatric Use
`8.5 Geriatric Use
`8.6 Renal Impairment
` 8.7 Hepatic Impairment
`10
`OVERDOSAGE
`11
`DESCRIPTION
`12
`CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`CLINICAL STUDIES
`14.1 Overview of Clinical Studies
`14.2 Monotherapy Use of OZEMPIC in Patients with Type 2
`Diabetes Mellitus
`14.3 Combination Therapy Use of OZEMPIC in Patients with Type 2
`Diabetes Mellitus
`14.4 Cardiovascular Outcomes Trial of OZEMPIC in Patients with
`Type 2 Diabetes Mellitus
`HOW SUPPLIED/STORAGE AND HANDLING
`16
`17 PATIENT COUNSELING INFORMATION
`
`*Sections or subsections omitted from the full prescribing information are not
`listed.
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`WARNING: RISK OF THYROID C-CELL TUMORS
`
`INDICATIONS AND USAGE
`DOSAGE AND ADMINISTRATION
`2.1 Recommended Dosage
`2.2 Important Administration Instructions
`DOSAGE FORMS AND STRENGTHS
`CONTRAINDICATIONS
`WARNINGS AND PRECAUTIONS
`5.1 Risk of Thyroid C-Cell Tumors
`5.2 Pancreatitis
`5.3 Diabetic Retinopathy Complications
`5.4 Never Share an OZEMPIC Pen Between Patients
`5.5 Hypoglycemia with Concomitant Use of Insulin
`Secretagogues or Insulin
`5.6 Acute Kidney Injury
`5.7 Hypersensitivity
`5.8 Macrovascular Outcomes
`ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`6.2 Immunogenicity
`DRUG INTERACTIONS
`7.1 Concomitant Use with an Insulin Secretagogue (e.g.
`Sulfonylurea) or Insulin
`7.2 Oral Medications
`
`
` 1
`
`
`2
`
`3
`4
`5
`
`6
`
`7
`
`
`
`
`1
`Reference ID: 4190425
`
`

`

`
`FULL PRESCRIBING INFORMATION
`
`WARNING: RISK OF THYROID C-CELL TUMORS
` In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid
`C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes
`thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human
`relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see
`Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
` OZEMPIC is contraindicated in patients with a personal or family history of MTC or in
`patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications
`(4)]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and
`inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea,
`persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is
`of uncertain value for early detection of MTC in patients treated with OZEMPIC [see
`Contraindications (4) and Warnings and Precautions (5.1)].
`
` 1
`
`INDICATIONS AND USAGE
`
`OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2
`diabetes mellitus [see Clinical Studies (14.1)].
`
`Limitations of Use
` OZEMPIC is not recommended as a first-line therapy for patients who have inadequate glycemic control on
`diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans [see Warnings
`and Precautions (5.1)].
` OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies
`in patients with a history of pancreatitis [see Warnings and Precautions (5.2)].
` OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes
`mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these
`settings.
`
` 2
`
`DOSAGE AND ADMINISTRATION
`
`Recommended Dosage
`2.1
` Start OZEMPIC with a 0.25 mg subcutaneous injection once weekly for 4 weeks. The 0.25 mg dose is
`intended for treatment initiation and is not effective for glycemic control.
`
` After 4 weeks on the 0.25 mg dose, increase the dosage to 0.5 mg once weekly.
`
`If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, the dosage may be
`increased to 1 mg once weekly. The maximum recommended dosage is 1 mg once weekly.
`
`
`
`
`
`
`
`
`
` Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without
`meals.
`
` The day of weekly administration can be changed if necessary as long as the time between two doses is
`at least 2 days (>48 hours).
`
`
`1
`Reference ID: 4190425
`
`

`

`
`
`
`
`If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose. If
`more than 5 days have passed, skip the missed dose and administer the next dose on the regularly
`scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
`
`2.2
`Important Administration Instructions
` Administer OZEMPIC subcutaneously to the abdomen, thigh, or upper arm. Instruct patients to use a
`different injection site each week when injecting in the same body region.
`
`
`
`
`
`
`
`Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if
`particulate matter and coloration is seen.
`
` When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never
`mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region but the
`injections should not be adjacent to each other.
`
` 3
`
`DOSAGE FORMS AND STRENGTHS
`
`Injection: 2 mg/1.5 mL (1.34 mg/mL) of semaglutide as a clear, colorless solution available in:
` Pre-filled, disposable, single-patient-use pen that delivers 0.25 mg (for treatment initiation) or 0.5 mg
`(for maintenance treatment) per injection
` Pre-filled, disposable, single-patient-use pen that delivers 1 mg (for maintenance treatment) per
`injection.
`
` 4
`
`CONTRAINDICATIONS
`
`OZEMPIC is contraindicated in patients with:
` A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple
`Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].
` Known hypersensitivity to semaglutide or to any of the product components [see Warnings and
`Precautions (5.7)].
`
` 5
`
`WARNINGS AND PRECAUTIONS
`
`Risk of Thyroid C-Cell Tumors
`5.1
`In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the
`incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant
`plasma exposures [see Nonclinical Toxicology (13.1)]. It is unknown whether OZEMPIC causes thyroid C-cell
`tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced
`rodent thyroid C-cell tumors has not been determined.
`
`Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the
`postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship
`between MTC and GLP-1 receptor agonist use in humans.
`
`OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
`Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms
`of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
`
`Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of
`MTC in patients treated with OZEMPIC. Such monitoring may increase the risk of unnecessary procedures, due
`to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly
`elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values >50
`
`1
`Reference ID: 4190425
`
`

`

`
`ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients
`with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
`
`5.2
`Pancreatitis
`In glycemic control trials, acute pancreatitis was confirmed by adjudication in 7 OZEMPIC-treated patients (0.3
`cases per 100 patient years) versus 3 in comparator-treated patients (0.2 cases per 100 patient years). One case
`of chronic pancreatitis was confirmed in an OZEMPIC-treated patient. In a 2-year trial, acute pancreatitis was
`confirmed by adjudication in 8 OZEMPIC-treated patients (0.27 cases per 100 patient years) and 10 placebo-
`treated patients (0.33 cases per 100 patient years), both on a background of standard of care.
`
`After initiation of OZEMPIC, observe patients carefully for signs and symptoms of pancreatitis (including
`persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied
`by vomiting). If pancreatitis is suspected, OZEMPIC should be discontinued and appropriate management
`initiated; if confirmed, OZEMPIC should not be restarted.
`
`5.3
`Diabetic Retinopathy Complications
`In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic
`retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%). The
`absolute risk increase for diabetic retinopathy complications was larger among patients with a history of
`diabetic retinopathy at baseline (OZEMPIC 8.2%, placebo 5.2%) than among patients without a known history
`of diabetic retinopathy (OZEMPIC 0.7%, placebo 0.4%).
`
`Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
`The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been
`studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic
`retinopathy.
`
`Never Share an OZEMPIC Pen Between Patients
`5.4
`OZEMPIC pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk
`for transmission of blood-borne pathogens.
`
`5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
`The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g.,
`sulfonylureas) or insulin. Patients may require a lower dose of the secretagogue or insulin to reduce the risk of
`hypoglycemia in this setting [see Adverse Reactions (6.1), Drug Interactions (7.1)].
`
`Acute Kidney Injury
`5.6
`There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which
`may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events
`have been reported in patients without known underlying renal disease. A majority of the reported events
`occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function
`when initiating or escalating doses of OZEMPIC in patients reporting severe adverse gastrointestinal reactions.
`
`5.7 Hypersensitivity
`Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor
`agonists. If hypersensitivity reactions occur, discontinue use of OZEMPIC; treat promptly per standard of care,
`and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity to
`OZEMPIC [see Contraindications (4)].
`
`
`
`1
`Reference ID: 4190425
`
`

`

`
`Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient
`with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown
`whether such patients will be predisposed to anaphylaxis with OZEMPIC.
`
`5.8 Macrovascular Outcomes
`There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with
`OZEMPIC.
`
`ADVERSE REACTIONS
`
`The following serious adverse reactions are described below or elsewhere in the prescribing information:
`
` 6
`
` •
`
` Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]
`• Pancreatitis [see Warnings and Precautions (5.2)]
`• Diabetic Retinopathy Complications [see Warnings and Precautions (5.3)]
`• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions
`(5.5)]
`• Acute Kidney Injury [see Warnings and Precautions (5.6)]
`• Hypersensitivity [see Warnings and Precautions (5.7)]
`
`6.1 Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the
`clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not
`reflect the rates observed in practice.
`
`Pool of Placebo-Controlled Trials
`The data in Table 1 are derived from 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination
`with basal insulin) in patients with type 2 diabetes [see Clinical Studies (14)]. These data reflect exposure of
`521 patients to OZEMPIC and a mean duration of exposure to OZEMPIC of 32.9 weeks. Across the treatment
`arms, the mean age of patients was 56 years, 3.4% were 75 years or older and 55% were male. In these trials
`71% were White, 7% were Black or African American, and 19% were Asian; 21% identified as Hispanic or
`Latino ethnicity. At baseline, patients had type 2 diabetes for an average of 8.8 years and had a mean HbA1c of
`8.2%. At baseline, 8.9% of the population reported retinopathy. Baseline estimated renal function was normal
`(eGFR ≥90 mL/min/1.73m2) in 57.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m2) in 35.9% and
`moderately impaired (eGFR 30 to 60 mL/min/1.73m2) in 6.9% of patients.
`
`Pool of Placebo- and Active-Controlled Trials
`The occurrence of adverse reactions was also evaluated in a larger pool of patients with type 2 diabetes
`participating in 7 placebo- and active-controlled glycemic control trials [see Clinical Studies (14)] including
`two trials in Japanese patients evaluating the use of OZEMPIC as monotherapy and add-on therapy to oral
`medications or insulin. In this pool, a total of 3150 patients with type 2 diabetes were treated with OZEMPIC
`for a mean duration of 44.9 weeks. Across the treatment arms, the mean age of patients was 57 years, 3.2%
`were 75 years or older and 57% were male. In these trials, 60% were White, 6% were Black or African
`American, and 31% were Asian; 16% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2
`diabetes for an average of 8.2 years and had a mean HbA1c of 8.2%. At baseline, 7.8% of the population
`reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m2) in 63.1%,
`mildly impaired (eGFR 60 to 90 mL/min/1.73m2) in 34.3%, and moderately impaired (eGFR 30 to 60
`mL/min/1.73m2) in 2.5% of the patients.
`
`
`
`
`1
`Reference ID: 4190425
`
`

`

`
`Common Adverse Reactions
`Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of OZEMPIC in the
`pool of placebo-controlled trials. These adverse reactions occurred more commonly on OZEMPIC than on
`placebo, and occurred in at least 5% of patients treated with OZEMPIC.
`
`Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated
`Patients with Type 2 Diabetes Mellitus
`Adverse Reaction
`Placebo
`(N=262)
`%
`6.1
`2.3
`1.9
`4.6
`1.5
`
`OZEMPIC 0.5 mg
`(N=260)
`%
`15.8
`5.0
`8.5
`7.3
`5.0
`
`OZEMPIC 1 mg
`(N=261)
`%
`20.3
`9.2
`8.8
`5.7
`3.1
`
`Nausea
`Vomiting
`Diarrhea
`Abdominal pain
`Constipation
`
`In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and
`frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1.
`
`Gastrointestinal Adverse Reactions
`In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among
`patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%).
`The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients
`receiving OZEMPIC 0.5 mg (3.1%) and OZEMPIC 1 mg (3.8%) discontinued treatment due to gastrointestinal
`adverse reactions than patients receiving placebo (0.4%).
`
`In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5%
`were associated with OZEMPIC (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%,
`3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%,
`1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%).
`
`
`Other Adverse Reactions
`Hypoglycemia
`
`Table 2 summarizes the incidence of events related to hypoglycemia by various definitions in the placebo-
`controlled trials.
`
`Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials In Patients with Type 2 Diabetes
`Mellitus
`
`
`Monotherapy
` (30 weeks)
` Severe†
`Documented symptomatic
`(≤70 mg/dL glucose
`threshold)
` Severe† or Blood Glucose
`Confirmed Symptomatic
`(≤56 mg/dL glucose
`
`
`1
`Reference ID: 4190425
`
`Placebo
`
`OZEMPIC 0.5 mg
`
`OZEMPIC 1 mg
`
`N=129
`0%
`0%
`
`1.6%
`
`N=127
`0%
`1.6%
`
`0%
`
`N=130
`0%
`3.8%
`
`0%
`
`

`

`5.3%
`
`8.3%
`
`N=131
`1.5%
`29.8%
`
`10.7%
`
`N=132
`0%
`16.7%
`
`threshold)
`Add-on to Basal Insulin with or without Metformin
` (30 weeks)
`N=132
` Severe†
`0%
`Documented symptomatic
`15.2%
`(≤70 mg/dL glucose
`threshold)
` Severe† or Blood Glucose
`Confirmed Symptomatic
`(≤56 mg/dL glucose
`threshold)
`† “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person.
`
`Hypoglycemia was more frequent when OZEMPIC was used in combination with a sulfonylurea [see Warnings
`and Precautions (5.5) and Clinical Studies (14)]. Severe hypoglycemia occurred in 0.8% and 1.2% of patients
`when OZEMPIC 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Documented
`symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when OZEMPIC 0.5 mg and 1 mg,
`respectively, was co-administered with a sulfonylurea. Severe or blood glucose confirmed symptomatic
`hypoglycemia occurred in 6.5% and 10.4% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was co-
`administered with a sulfonylurea.
`
`Injection Site Reactions
`In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in
`0.2% of OZEMPIC-treated patients.
`
`Increases in Amylase and Lipase
`In placebo-controlled trials, patients exposed to OZEMPIC had a mean increase from baseline in amylase of
`13% and lipase of 22%. These changes were not observed in placebo-treated patients.
`
`Cholelithiasis
`In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC
`0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients.
`
`Increases in Heart Rate
`In placebo-controlled trials, OZEMPIC 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats
`per minute. There was a mean decrease in heart rate of 0.3 beats per minute in placebo-treated patients.
`
`Fatigue, Dysgeusia and Dizziness
`Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia
`and dizziness.
`
`Immunogenicity
`6.2
`Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients treated
`with OZEMPIC may develop anti-semaglutide antibodies. The detection of antibody formation is highly
`dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody
`(including neutralizing antibody) positivity in an assay may be influenced by several factors including assay
`methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
`For these reasons, the incidence of antibodies to semaglutide in the studies described below cannot be directly
`compared with the incidence of antibodies in other studies or to other products.
`
`
`
`
`1
`Reference ID: 4190425
`
`

`

`
`
`Across the placebo- and active-controlled glycemic control trials, 32 (1.0%) OZEMPIC-treated patients
`developed anti-drug antibodies (ADAs) to the active ingredient in OZEMPIC (i.e., semaglutide). Of the 32
`semaglutide-treated patients that developed semaglutide ADAs, 19 patients (0.6% of the overall population)
`developed antibodies cross-reacting with native GLP-1. The in vitro neutralizing activity of the antibodies is
`uncertain at this time.
`
` 7
`
`DRUG INTERACTIONS
`
`7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
`The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g.,
`sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea
`(or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)].
`
`7.2 Oral Medications
`OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of
`concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the
`absorption of orally administered medications to any clinically relevant degree [see Clinical Pharmacology
`(12.3)]. Nonetheless, caution should be exercised when oral medications are concomitantly administered with
`OZEMPIC.
`
`USE IN SPECIFIC POPULATIONS
`8
`Pregnancy
`8.1
`Risk Summary
`There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse
`developmental outcomes. There are clinical considerations regarding the risks of poorly controlled diabetes in
`pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be potential risks to
`the fetus from exposure to semaglutide during pregnancy. OZEMPIC should be used during pregnancy only if
`the potential benefit justifies the potential risk to the fetus.
`
`In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities
`and alterations to growth occurred at maternal exposures below the maximum recommended human dose
`(MRHD) based on AUC. In rabbits and cynomolgus monkeys administered semaglutide during organogenesis,
`early pregnancy losses and structural abnormalities were observed at below the MRHD (rabbit) and ≥5-fold the
`MRHD (monkey). These findings coincided with a marked maternal body weight loss in both animal species
`(see Data).
`
`The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an
`HbA1c >7 and has been reported to be as high as 20–25% in women with a HbA1c >10. In the U.S. general
`population, the estimated background risk of major birth defects and miscarriage in clinically recognized
`pregnancies is 2-4% and 15-20%, respectively.
`
`Clinical Considerations
`Disease associated maternal and fetal risk
`Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-
`eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled
`diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.
`
`Data
`Animal Data
`
`
`1
`Reference ID: 4190425
`
`

`

`
`In a combined fertility and embryofetal development study in rats, subcutaneous doses of 0.01, 0.03 and 0.09
`mg/kg/day (0.1-, 0.4-, and 1.1-fold the MRHD) were administered to males for 4 weeks prior to and throughout
`mating and to females for 2 weeks prior to mating, and throughout organogenesis to Gestation Day 17. In
`parental animals, pharmacologically mediated reductions in body weight gain and food consumption were
`observed at all dose levels. In the offspring, reduced growth and fetuses with visceral (heart blood vessels) and
`skeletal (cranial bones, vertebra, ribs) abnormalities were observed at the human exposure.
`
`In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.0010, 0.0025 or 0.0075
`mg/kg/day (0.03-, 0.3-, and 2.3-fold the MRHD) were administered throughout organogenesis from Gestation
`Day 6 to 19. Pharmacologically mediated reductions in maternal body weight gain and food consumption were
`observed at all dose levels. Early pregnancy losses and increased incidences of minor visceral (kidney, liver)
`and skeletal (sternebra) fetal abnormalities were observed at ≥0.0025 mg/kg/day, at clinically relevant
`exposures.
`
`In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075,
`and 0.15 mg/kg twice weekly (1.0-, 5.2-, and 14.9-fold the MRHD) were administered throughout
`organogenesis, from Gestation Day 16 to 50. Pharmacologically mediated, marked initial maternal body weight
`loss and reductions in body weight gain and food consumption coincided with the occurrence of sporadic
`abnormalities (vertebra, sternebra, ribs) at ≥0.075 mg/kg twice weekly (>5X human exposure).
`
`In a pre- and postnatal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015,
`0.075, and 0.15 mg/kg twice weekly (0.7-, 3.3-, and 7.2-fold the MRHD) were administered from Gestation
`Day 16 to 140. Pharmacologically mediated marked initial maternal body weight loss and reductions in body
`weight gain and food consumption coincided with an increase in early pregnancy losses and led to delivery of
`slightly smaller offspring at ≥0.075 mg/kg twice weekly (>3X human exposure).
`
`Lactation
`8.2
`Risk Summary
`There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the
`effects on milk production. Semaglutide was present in the milk of lactating rats, however, due to species-
`specific differences in lactation physiology, the clinical relevance of these data are not clear (see Data). The
`developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need
`for OZEMPIC and any potential adverse effects on the breastfed infant from OZEMPIC or from the underlying
`maternal condition.
`
`Data
`In lactating rats, semaglutide was detected in milk at levels 3-12 fold lower than in maternal plasma.
`
`Females and Males of Reproductive Potential
`8.3
`Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period
`for semaglutide [see Use in Specific Populations (8.1)].
`
`Pediatric Use
`8.4
`Safety and efficacy of OZEMPIC have not been established in pediatric patients (younger than 18 years).
`
`8.5 Geriatric Use
`In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC-treated patients
`were 65 years of age and over and 102 OZEMPIC-treated patients (3.2%) patients were 75 years of age and
`over. In SUSTAIN 6, the cardiovascular outcome trial, 788 (48.0%) OZEMPIC-treated patients were 65 years
`of age and over and 157 OZEMPIC-treated patients (9.6%) patients were 75 years of age and over.
`
`1
`Reference ID: 4190425
`
`

`

`
`
`No overall differences in safety or efficacy were detected between these patients and younger patients, but
`greater sensitivity of some older individuals cannot be ruled out.
`
`Renal Impairment
`8.6
`No dose adjustment of OZEMPIC is recommended for patients with renal impairment. In subjects with renal
`impairment including end-stage renal disease (ESRD), no clinically relevant change in semaglutide
`pharmacokinetics (PK) was observed [see Clinical Pharmacology (12.3)].
`
`8.7 Hepatic Impairment
`No dose adjustment of OZEMPIC is recommended for patients with hepatic

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket